Document is current
Any future updates will be listed below
-
Authors
Gigi, Elinor
Gavert, Nancy https://orcid.org/0000-0003-1639-4684
Raijman-Nagar, Lilach
Zwang, Yaara https://orcid.org/0000-0002-5387-4663
Zemach, Hofit
Livyatan, Ilana
Levy-Barda, Adva
Laviv, Yossi
Kanner, Andrew A. https://orcid.org/0000-0002-0812-8573
Amiel, Alexandra
Siegal, Tali
Leibovici, Anca
Selezen, Inna
Badran, Omar
Zohar, Yaniv
Safadi, Esraa
Prather, Lyndsey L.
Helfer, Cassandra R.
Castro, Patricia https://orcid.org/0000-0001-5286-8037
Barshack, Iris
Dadosh, Tali
Levin-Zaidman, Smadar
Goliand, Inna
Golani, Ofra https://orcid.org/0000-0002-9793-236X
Horn, Suzana
Mandel, Jacob J.
Shental, Noam
Shai, Ayelet https://orcid.org/0000-0001-9502-8441
Yust-Katz, Shlomit
Straussman, Ravid https://orcid.org/0000-0002-9476-329X
-
Funding
Funding for this research was provided by:
Israel Cancer Research Fund (22-109-PG)
Israel Science Foundation (2927/21)
EC | Horizon 2020 Framework Programme (818086)
- License Information
-
More Information
Article History
Received: 29 November 2024
Accepted: 10 October 2025
First Online: 14 November 2025
Change Date: 19 January 2026
Change Type: Update
Change Details: In the version of Source Data Fig. 3 initially published alongside this article, some values in the Fig. 3b table were incorrect. An updated Source Data Fig. 3 file is available in the HTML version of this article.
Competing interests
: R.S. reports stock interest in CuResponse, Baccine and Gnomica and is a paid adviser to these companies. N.G. reports stock interest in CuResponse and is a paid advisor of CuResponse. The other authors declare no competing interests.
